The 2019 Nobel Prize honors fundamental discoveries in hypoxia response

被引:20
作者
Moslehi, Javid [1 ,2 ]
Rathmell, W. Kimryn [2 ,3 ]
机构
[1] VUMC, Div Cardiovasc Med, Cardiooncol Program, Nashville, TN USA
[2] VUMC, Dept Med, Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[3] VUMC, Div Hematol & Oncol, 2220 Pierce Ave,Preston Res Bldg,Suite 798C, Nashville, TN 37232 USA
关键词
HIF-ALPHA; FAMILY; PURIFICATION; COMPLEX; GENE;
D O I
10.1172/JCI134813
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The 2019 Nobel Prize for Physiology or Medicine was awarded to Professors Sir Peter J. Ratcliffe (University of Oxford), Gregg L. Semenza (Johns Hopkins University), and William G. Kaelin Jr. (Dana-Farber Cancer Institute) for their discoveries of a fundamental aspect of cellular physiology, the cellular sensing of oxygen levels and regulation of physiologic hypoxia. Each of these physician-scientists was intrigued by a different clinically relevant observation and utilized very basic biochemical tools to address their questions. These separate lines of investigation converged, delineating a central cellular pathway with farranging implications for human physiology, disease states, and medicine. The story of how they uncovered hypoxia response begins with a deep interest in basic human biology. Uncovering a hypoxia-inducible pathway Semenza, a pediatric geneticist, was studying the triggers for the production of erythropoietin, a hematopoietic growth factor produced by the liver and kidney that promotes the generation of red blood cells. His group identified a sequence-specific binding site (termed hypoxia-response element [HRE]) for a transcription factor in the 3 flanking region of the human erythropoietin gene (EPO). He biochemically purified the factor, which he called hypoxia-inducible factor 1 (HIF-1) (1). HIF-1 is a heterodimer composed of HIF-1a, a protein expressed in an oxygen-regulated manner, and a constitutively expressed factor, HIF-1b. This dimer formed a potent transcription factor complex, and Semenza showed that []. © 2020, American Society for Clinical Investigation.
引用
收藏
页码:4 / 6
页数:3
相关论文
共 19 条
[1]   A conserved family of prolyl-4-hydroxylases that modify HIF [J].
Bruick, RK ;
McKnight, SL .
SCIENCE, 2001, 294 (5545) :1337-1340
[2]   Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis [J].
Chen, N. ;
Hao, C. ;
Peng, X. ;
Lin, H. ;
Yin, A. ;
Hao, L. ;
Tao, Y. ;
Liang, X. ;
Liu, Z. ;
Xing, C. ;
Chen, J. ;
Luo, L. ;
Zuo, L. ;
Liao, Y. ;
Liu, B-C ;
Leong, R. ;
Wang, C. ;
Liu, C. ;
Neff, T. ;
Szczech, L. ;
Yu, K-H P. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (11) :1001-1010
[3]   Phase I Dose-Escalation Trial of PT2385, a First-in-Class Hypoxia-Inducible Factor-2α Antagonist in Patients With Previously Treated Advanced Clear Cell Renal Cell Carcinoma [J].
Courtney, Kevin D. ;
Infante, Jeffrey R. ;
Lam, Elaine T. ;
Figlin, Robert A. ;
Rini, Brian I. ;
Brugarolas, James ;
Zojwalla, Naseem J. ;
Lowe, Ann M. ;
Wang, Keshi ;
Wallace, Eli M. ;
Josey, John A. ;
Choueiri, Toni K. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) :867-+
[4]   C-elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation [J].
Epstein, ACR ;
Gleadle, JM ;
McNeill, LA ;
Hewitson, KS ;
O'Rourke, J ;
Mole, DR ;
Mukherji, M ;
Metzen, E ;
Wilson, MI ;
Dhanda, A ;
Tian, YM ;
Masson, N ;
Hamilton, DL ;
Jaakkola, P ;
Barstead, R ;
Hodgkin, J ;
Maxwell, PH ;
Pugh, CW ;
Schofield, CJ ;
Ratcliffe, PJ .
CELL, 2001, 107 (01) :43-54
[5]  
Forsythe JA, 1996, MOL CELL BIOL, V16, P4604
[6]   Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor [J].
Ivan, M ;
Haberberger, T ;
Gervasi, DC ;
Michelson, KS ;
Günzler, V ;
Kondo, K ;
Yang, HF ;
Sorokina, I ;
Conaway, RC ;
Conaway, JW ;
Kaelin, WG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13459-13464
[7]   HIFα targeted for VHL-mediated destruction by proline hydroxylation:: Implications for O2 sensing [J].
Ivan, M ;
Kondo, K ;
Yang, HF ;
Kim, W ;
Valiando, J ;
Ohh, M ;
Salic, A ;
Asara, JM ;
Lane, WS ;
Kaelin, WG .
SCIENCE, 2001, 292 (5516) :464-468
[8]   Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation [J].
Jaakkola, P ;
Mole, DR ;
Tian, YM ;
Wilson, MI ;
Gielbert, J ;
Gaskell, SJ ;
von Kriegsheim, A ;
Hebestreit, HF ;
Mukherji, M ;
Schofield, CJ ;
Maxwell, PH ;
Pugh, CW ;
Ratcliffe, PJ .
SCIENCE, 2001, 292 (5516) :468-472
[9]   Regulation of hypoxia-inducible mRNAs by the von Hippel-Lindau tumor suppressor protein requires binding to complexes containing elongins B/C and Cul2 [J].
Lonergan, KM ;
Iliopoulos, O ;
Ohh, M ;
Kamura, T ;
Conaway, RC ;
Conaway, JW ;
Kaelin, WG .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (02) :732-741
[10]   The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis [J].
Maxwell, PH ;
Wiesener, MS ;
Chang, GW ;
Clifford, SC ;
Vaux, EC ;
Cockman, ME ;
Wykoff, CC ;
Pugh, CW ;
Maher, ER ;
Ratcliffe, PJ .
NATURE, 1999, 399 (6733) :271-275